September 15, 2010 | Expiration date:
September 28, 2011
Estimated time to complete activity:
Type of activity:
Knowledge | Media:
This activity is supported by an educational grant from Teva Neurosciences, Inc.
The audience for this supplement consists of medical directors, pharmacy directors, and other managed care professionals who oversee the care of patients with multiple sclerosis.
Statement of Educational Need/Program Overview
This educational activity will educate and inform managed care professionals on new and emerging oral therapies for multiple sclerosis (MS), including considerations for appropriate use and issues that may impact their accessibility by patients and providers.
A new generation of MS therapies is currently emerging, including agents possessing mechanisms of action not previously applied to the treatment of MS and new oral formulations. Efficacy data for these new agents are generally positive, although there are concerns that may restrict the use of these drugs in the overall MS population.
Although it remains to be seen how widespread the emergent therapies will become and whether they will displace the dominant disease-modifying therapies, this shifting landscape of MS treatment options has the potential to significantly change therapeutic strategies over the next several years. Despite this shift, there are relatively few examples of up-to-date summaries of the state of progress in MS therapy in the medical literature, particularly with regard to the concerns of the managed care audience.
After completing this activity, the participant should be able to:
Review the advantages, as well as limitations, and unmet treatment needs associated with the currently available multiple sclerosis (MS) therapies.
Discuss the current approaches to measuring efficacy in MS treatment, including the use of magnetic resonance imaging techniques.
Compare and contrast the relative efficacy and safety profiles of the new generation of oral MS therapies.
Cite the key points of debate regarding issues of access to emerging MS treatment with regard to the role of managed care.
Identify the likely barriers to access of these new MS agents, and what will be required to overcome them for patients and clinicians to be able to take full advantage of the safest and most effective available MS therapies.
According to the disclosure policies of the University of Cincinnati and Pharmacy Times Office of Continuing Professional Education, faculty, editors, managers, and other individuals who are in a position to control content are required to disclose any relevant financial relationships with relevant commercial companies related to this activity. All relevant conflicts of interest that are identified are reviewed for potential conflicts of interest. If a conflict is identified, it is the responsibility of the University of Cincinnati and Pharmacy Times Office of Continuing Professional Education to initiate a mechanism to resolve the conflict(s). The existence of these interests or relationships is not viewed as implying bias or decreasing the value of the presentation.
All educational materials are reviewed for fair balance, scientific objectivity of studies reported, and levels of evidence.
Physician Continuing Medical Education
Accreditation Statement / Credit Designation
This activity has been planned and implemented in accordance with the Essential Areas and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the University of Cincinnati. The University of Cincinnati is accredited by the ACCMEto provide continuing medical education for physicians.
The University of Cincinnati designates this educational activity for a maximum of 2 AMA PRA Category 1 Credit(s)
™. Physicians should only claim credit commensurate with the extent of their participation in the activity.
Pharmacist Continuing Education
Pharmacy Times Office of Continuing Professional Education is accredited by the Accreditation Council for Pharmacy Education (ACPE) as a provider of continuing pharmacy education. This program is approved for 2 contact hours (0.20 CEUs) under the ACPEuniversal program number of 0290-9999-10-018-H01-P. This program is available for CE credit through September 28, 2011.
Edward J. Fox, MD, PhD
Central Texas Neurology Consultants - Round Rock, Texas
Robert J. Lipsy, PharmD, FASHP, BCPS
Clinical Assistant ProfessorUniversity of Arizona, College of Pharmacy - Tucson, Arizona
Clyde E. Markowitz, MD
Director, Multiple Sclerosis Center
Associate Professor of Neurology, University of Pennsylvania - Philadelphia, PA
These faculty have disclosed the following relevant commercial financial relationships or affiliations in the past 12 months.
Edward J. Fox, MD, PhD
Bayer, Biogen Idec, EMD Serono, Genzyme, Pfizer, Opexa, Teva
Biogen Idec, EMD Serono, Genzyme, Opexa, Ono, sanofi-aventis, Teva
Honoraria/lectureship/meeting and conference attendance:
Bayer, Biogen Idec, EMD Serono, Teva
Robert J. Lipsy, PharmD, FASHP, BCPS,
has nothing relevant to disclose.
Clyde E. Markowitz, MD
Bayer, Biogen Idec, EMD Serono, Novartis, Teva, Wyeth
Bayer, Biogen Idec, EMD Serono, Novartis, Teva
The planning staff from the University of Cincinnati, The American Journal of Managed Care
, and the Pharmacy Times Office of Continuing Professional Education have no relevant financial relationships to disclose. Signed disclosures are on file at the office of The American Journal of Managed Care
, Plainsboro, New Jersey.
Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications on dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.
The contents of this supplement may include information regarding the use of products that may be inconsistent with or outside the approved labeling for these products in the United States. Physicians should note that the use of these products outside current approved labeling is considered experimental and are advised to consult prescribing information for these products.
Required: Windows® 7, Vista, XP, 2003 Server or 2000
Required: Mac OS® X 10.4.11 (Tiger®) or newer
© 2010 Managed Care & Healthcare Communications, LLC